The GLAM project, which has received funding from the European Union\u2019s Horizon 2020\u00a0programme, involves three spanish partners\u00a0\u2013Leitat (coordinator),\u00a0IBEC and\u00a0the Institute of Photonic Sciences, ICFO (Spain)\u2013\u00a0and the\u00a0University of Twente and\u00a0Radboud University Medical Center (The Netherlands), the Free University of Brussels and the Obelis Group (Belgium), Novelic (Serbia),\u00a0WizSoft (Israel)\u00a0and OptoCap (UK).<\/p>\n
The members of the consortium will combine medical research with basic research and biotechnology to develop in a four-year term a new diagnostic tool to detect biomarkers from biofluids obtained in a non-invasive manner, focusing on urine and genitourinary cancers. The project will develop an integrated device based on novel label-free photonic biosensors with ultra-sensitivity, simplicity of use, portability, multiplexing and low cost.<\/p>\n
\u201cMost cancer biopsies must be analyzed in specialized laboratories, which involves high costs and long waiting periods, as they require specialised personnel and equipment,\u201d says the\u00a0project coordinator,\u00a0Izabel Alfany,\u00a0International Project Manager-Healthcare at Leitat. \u201cThere is therefore a real need and urgency to have new devices that provide diagnosis, prognosis, and data monitoring faster and with exceptional ultra-sensitivity,\u201d explains the\u00a0research project director,\u00a0Francesc Mitjans, director of the Biomed Division at Leitat.<\/p>\n
Elena Mart\u00ednez, senior researcher at IBEC says: \u201cThe device will make use of the unprecedented sensitivity that can be achieved using laser micro-ring resonators \u2013 devices using the same principle as a whispering gallery, but with light instead of sound.\u201d<\/p>\n
Last, the unique GLAM technology will have the potential to be used with other types of biofluids, opening the way to the diagnosis and monitoring of other kinds of cancer and many more diseases.<\/p>\n","protected":false},"excerpt":{"rendered":"
A European consortium led by\u00a0Centre Tecnol\u00f2gic Leitat<\/a>\u00a0\u2013through its\u00a0Biomed Division<\/a>,\u00a0<\/a>located at the Barcelona Science Park (PCB)\u2013 has started the\u00a0Glass-Laser Multiplexed Biosensor (GLAM)<\/a>\u00a0project, the aim of which is to develop a\u00a0photonic-based point-of-care\u00a0device for a non-invasive diagnosis\u00a0of Genitourinary Cancer (GU). The GLAM project which will expand for 4 years will involve the participation of 10 European organizations with resources and capabilities from the academia and scientific and business field, among them the Institute for Bioengineering of Catalonia (IBEC)<\/a>, located at PCB.\u00a0<\/p>\n \u00a0<\/p>\n","protected":false},"author":1,"featured_media":53107,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[8],"tags":[],"class_list":["post-49485","post","type-post","status-publish","format-standard","has-post-thumbnail","category-uncategorized"],"acf":[],"yoast_head":"\n